← Back to Screener
Daxor Corporation Common Stock (DXR)
Price$10.60
Value ScoreD
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-27.93%
Price vs S&P 500 (4W)-2.33%
VGM Score40.51
Market Capitalization$58.22M
P/E Ratio (Annual)6.35x
All Metrics
P/CF (Annual)101.97x
Book Value / Share (Quarterly)$9.07
P/TBV (Annual)2.05x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-51.22%
Cash Flow / Share (Quarterly)$0.11
Price vs S&P 500 (YTD)-34.75%
Gross Margin (TTM)-3917.23%
Net Profit Margin (TTM)34356.61%
EPS (TTM)$1.98
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$1.98
Revenue Growth (5Y)-36.57%
EPS (Annual)$1.81
ROI (Annual)19.98%
Gross Margin (Annual)-3917.23%
Net Profit Margin (5Y Avg)7784.99%
Cash / Share (Quarterly)$0.02
P/E Basic Excl Extra (TTM)6.35x
Revenue Growth QoQ (YoY)-82.61%
P/E Normalized (Annual)6.35x
ROA (Last FY)19.93%
Revenue Growth TTM (YoY)-77.71%
EBITD / Share (TTM)$-0.22
ROE (5Y Avg)12.52%
Operating Margin (TTM)-4207.42%
Cash Flow / Share (Annual)$0.11
P/B Ratio1.27x
P/B Ratio (Quarterly)1.59x
EV / Revenue (TTM)2181.32x
Net Interest Coverage (TTM)-0.38x
ROA (TTM)22.39%
EPS Growth QoQ (YoY)329.99%
EV / EBITDA (TTM)5821.93x
EPS Incl Extra (Annual)$1.81
Current Ratio (Annual)0.08x
Quick Ratio (Quarterly)0.08x
3-Month Avg Trading Volume0.01M
52-Week Price Return26.49%
EV / Free Cash Flow (Annual)101.97x
P/E Incl Extra (TTM)6.35x
Tangible BV / Share (Quarterly)$6.33
P/S Ratio (Annual)2181.32x
Asset Turnover (Annual)0.00x
52-Week High$14.76
Operating Margin (5Y Avg)-1352.68%
EPS Excl Extra (Annual)$1.81
Tangible BV CAGR (5Y)16.06%
26-Week Price Return-20.00%
Quick Ratio (Annual)0.08x
13-Week Price Return-6.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.08x
Enterprise Value$58.22M
Revenue / Share Growth (5Y)-39.61%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)18.24%
Inventory Turnover (Annual)1.86x
Pretax Margin (Annual)34356.58%
Cash / Share (Annual)$0.02
3-Month Return Std Dev51.63%
Gross Margin (5Y Avg)-1212.70%
ROE (Last FY)19.98%
Net Interest Coverage (Annual)-4.58x
EPS Basic Excl Extra (Annual)$1.81
P/FCF (TTM)101.97x
Receivables Turnover (TTM)7.25x
EV / Free Cash Flow (TTM)101.97x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.98
Receivables Turnover (Annual)7.25x
ROI (TTM)22.43%
P/S Ratio (TTM)2181.32x
Pretax Margin (5Y Avg)7784.99%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$7.15
Free OCF CAGR (5Y)-61.68%
Price vs S&P 500 (52W)2.13%
P/E Ratio (TTM)6.35x
EPS Growth TTM (YoY)1068.54%
Year-to-Date Return-28.14%
5-Day Price Return5.37%
EPS Normalized (Annual)$1.81
ROA (5Y Avg)11.66%
Net Profit Margin (Annual)34356.58%
Month-to-Date Return3.11%
EBITD / Share (Annual)$-0.22
EPS Growth (3Y)14.49%
Operating Margin (Annual)-4207.38%
LT Debt / Equity (Annual)0.01x
P/CF (TTM)101.97x
ROI (5Y Avg)11.81%
P/E Excl Extra (TTM)6.35x
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$1.98
P/TBV (Quarterly)1.25x
P/B Ratio (Annual)1.59x
Inventory Turnover (TTM)1.89x
Pretax Margin (TTM)34356.61%
Book Value / Share (Annual)$9.07
Price vs S&P 500 (13W)-15.11%
Beta0.24x
P/FCF (Annual)101.97x
Revenue / Share (TTM)$0.01
ROE (TTM)22.50%
52-Week Low$8.08
vGradeD
gGradeD
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DXRDaxor Corporation Common Stock | D | D | B | $10.60 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Daxor Corp is a medical instrumentation company specializing in blood volume diagnostics. The company develops and markets the BVA-100 (Blood Volume Analyzer), an FDA-cleared diagnostic tool that provides accurate, objective measurement of blood volume status and composition across a broad range of medical conditions. By comparing results to patient-specific norms, the BVA-100 enables clinicians to make data-driven treatment decisions.